Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated liposomal doxorubicin
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Pegylated liposomal doxorubicin is a formulation of the anthracycline antibiotic doxorubicin encapsulated in long-circulating, polyethylene glycol (PEG)-coated liposomes. The PEG coating (pegylation) protects the drug from detection by the mononuclear phagocyte system and prolongs its circulation time in blood. This unique delivery system allows for enhanced accumulation of the drug in tumor tissues due to leaky tumor vasculature, while reducing exposure to normal tissues. The mechanism of action is through intercalation into DNA and inhibition of topoisomerase II, leading to inhibition of DNA replication and cell death. Pegylated liposomal doxorubicin is primarily used for treating breast cancer, ovarian cancer, multiple myeloma, and HIV-related Kaposi's sarcoma.
- Brand names
- Caelyx
- Other names
- pegylated liposomal doxorubicin hydrochlorideStealth liposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)DNA
Beyond the preview
Go deeper on pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated liposomal doxorubicin.